niacinamide has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, J; Cheng, Y; Duan, J; Gao, X; Wu, H; Yang, Y; You, L; Zhang, L; Zhang, X; Zhu, Q | 1 |
| Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H | 1 |
1 trial(s) available for niacinamide and mdv 3100
| Article | Year |
|---|---|
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
1 other study(ies) available for niacinamide and mdv 3100
| Article | Year |
|---|---|
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |